Carl-Magnus Högerkorp recently assumed the role as acting CEO of Cyxone. The biopharmaceutical company is currently awaiting approval of the phase II study with the candidate Rabeximod in rheumatoid arthritis. At the BioStock Investor Meeting in Stockholm, Högerkorp talked about the preparations for the start of the study and what lies ahead for the company.
See Cyxone’s presentation below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.